Quanterix Corp QTRX
We take great care to ensure that the data presented and summarized in this overview for Quanterix Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding QTRX
View all-
Ameriprise Financial Inc Minneapolis, MN3.72MShares$18 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.14MShares$15.2 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA2.96MShares$14.4 Million1.58% of portfolio
-
Kent Lake Pr LLC Anasco, PR2.92MShares$14.2 Million8.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.53MShares$12.2 Million0.0% of portfolio
-
Easterly Investment Partners LLC1.33MShares$6.43 Million0.73% of portfolio
-
Ubs Group Ag1.11MShares$5.41 Million0.0% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.11MShares$5.36 Million0.02% of portfolio
-
Invenomic Capital Management LP Boston, MA902KShares$4.37 Million0.29% of portfolio
-
Geode Capital Management, LLC Boston, MA866KShares$4.2 Million0.0% of portfolio
Latest Institutional Activity in QTRX
Top Purchases
Top Sells
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Insider Transactions at QTRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2025
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-0.27%
|
$916
$4.5 P/Share
|
May 15
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,242
-0.26%
|
$4,968
$4.5 P/Share
|
Apr 30
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
254
-0.05%
|
$1,270
$5.76 P/Share
|
Apr 15
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,242
-0.26%
|
$6,210
$5.16 P/Share
|
Apr 15
2025
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-0.27%
|
$1,145
$5.36 P/Share
|
Apr 01
2025
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
2,479
+0.8%
|
$14,874
$6.66 P/Share
|
Apr 01
2025
|
David R Walt |
BUY
Grant, award, or other acquisition
|
Direct |
2,156
+0.14%
|
$12,936
$6.66 P/Share
|
Apr 01
2025
|
William P Donnelly |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+5.51%
|
$16,086
$6.66 P/Share
|
Apr 01
2025
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
2,625
+4.37%
|
$15,750
$6.66 P/Share
|
Mar 31
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
254
-0.05%
|
$1,524
$6.51 P/Share
|
Mar 15
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,242
-0.26%
|
$8,694
$7.06 P/Share
|
Mar 15
2025
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-0.27%
|
$1,603
$7.06 P/Share
|
Feb 28
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
247
-0.05%
|
$1,729
$7.59 P/Share
|
Feb 15
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-0.16%
|
$6,016
$8.05 P/Share
|
Feb 15
2025
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-0.11%
|
$736
$8.05 P/Share
|
Feb 04
2025
|
Masoud Toloue President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
138,790
+22.48%
|
-
|
Feb 04
2025
|
Vandana Sriram Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,712
+37.5%
|
-
|
Feb 02
2025
|
Vandana Sriram Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,166
-6.02%
|
$19,494
$9.19 P/Share
|
Feb 02
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,077
-1.76%
|
$54,693
$9.19 P/Share
|
Jan 31
2025
|
Masoud Toloue President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
298
-0.09%
|
$2,682
$9.19 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 295K shares |
---|---|
Open market or private purchase | 66K shares |
Payment of exercise price or tax liability | 27.9K shares |
---|